GemPharmatech Co Ltd
SSE:688046
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
GemPharmatech Co Ltd
Total Current Assets
GemPharmatech Co Ltd
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
GemPharmatech Co Ltd
SSE:688046
|
Total Current Assets
¥1.7B
|
CAGR 3-Years
34%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Total Current Assets
¥61.7B
|
CAGR 3-Years
37%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Total Current Assets
¥7.8B
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Total Current Assets
¥28.1B
|
CAGR 3-Years
15%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Total Current Assets
¥6.2B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
25%
|
|
|
W
|
WuXi XDC Cayman Inc
HKEX:2268
|
Total Current Assets
¥10.1B
|
CAGR 3-Years
93%
|
CAGR 5-Years
152%
|
CAGR 10-Years
N/A
|
|
GemPharmatech Co Ltd
Glance View
GemPharmatech Co., Ltd. engages in research and development, manufacture, and sale of experimental mouse models. The company is headquartered in Nanjing, Jiangsu and currently employs 1,342 full-time employees. The company went IPO on 2022-04-25. The firm uses gene-editing and other technologies to produce mouse models. The firm also involves in the business of customized model breeding, drug efficacy analysis, and model customization. The Company’s products are mainly used to satisfy the experimental demands in the fields of gene function cognition, disease mechanisms analysis, drug target discovery, and other fundamental researches.
See Also
What is GemPharmatech Co Ltd's Total Current Assets?
Total Current Assets
1.7B
CNY
Based on the financial report for Dec 31, 2024, GemPharmatech Co Ltd's Total Current Assets amounts to 1.7B CNY.
What is GemPharmatech Co Ltd's Total Current Assets growth rate?
Total Current Assets CAGR 5Y
39%
Over the last year, the Total Current Assets growth was 3%. The average annual Total Current Assets growth rates for GemPharmatech Co Ltd have been 34% over the past three years , 39% over the past five years .
